Trial reportBJOG : an international journal of obstetrics and gynaecology2020
Effects of tocolysis with nifedipine or atosiban on child outcome: follow-up of the APOSTEL III trial.
Trial report in BJOG : an international journal of obstetrics and gynaecology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07146451 (6-year Follow-up of Children Born to Mothers Exposed to Nifedipine vs Placebo After Preterm Prelabor Rupture of Membranes at 22 to 33 Weeks of Gestation), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
6-year Follow-up of Children Born to Mothers Exposed to Nifedipine vs Placebo After Preterm Prelabor Rupture of Membranes at 22 to 33 Weeks of Gestation
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Tocolysis with nifedipine versus atosiban and perinatal outcome: an individual participant data meta-analysis.BMC pregnancy and childbirth · 2022Pooled it
- Prenatal 17-Alpha-Hydroxyprogesterone Caproate Exposure in Twins and Childhood Outcomes: 14-Year Follow-Up of a Randomised Trial.BJOG : an international journal of obstetrics and gynaecology · 2026Trial
- Long-term child outcomes after prenatal aspirin exposure: A 4-year follow-up of a randomized controlled trial (the APRIL study).International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Trial
- Effects of tocolysis with nifedipine or atosiban on child outcome: follow-up of the APOSTEL III trial.BJOG : an international journal of obstetrics and gynaecology · 2020Trial
- Psychomotor development, emotional regulation, and executive functions in 2-years-old children after threatened preterm labour: a prospective cohort study.European child & adolescent psychiatry · 2025Article
- Differences between Current Clinical Practice and Evidence-Based Guideline Recommendations Regarding Tocolysis - an Austria-wide Survey.Geburtshilfe und Frauenheilkunde · 2025Article
- Tocolysis and Neurodevelopment of Children Born Very Preterm.JAMA network open · 2024Article
- Article
- Article
- Article
- Hexoprenaline Compared with Atosiban as Tocolytic Treatment for Preterm Labor.Geburtshilfe und Frauenheilkunde · 2022Article
- Short-Term Outcomes of Atosiban in the Treatment of Preterm Labour at the Sultan Qaboos University Hospital, Muscat, Oman: A tertiary care experience.Sultan Qaboos University medical journal · 2021Article
- Corrigendum.BJOG : an international journal of obstetrics and gynaecology · 2021Article
Corrections and comments
- Commented on by
- Erratum issuedCorrigendum.2021
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
Abstract
objectiveTo compare the long-term effects of tocolysis with nifedipine or atosiban on child outcome at age 2.5-5.5 years.
designThe APOSTEL III trial was a multicentre randomised controlled trial that compared tocolysis with nifedipine or atosiban in 503 women with threatened preterm birth. Neonatal outcomes did not differ between both treatment arms, except for a higher incidence of intubation in the atosiban group.
methodsParents were asked to complete four questionnaires regarding neurodevelopment, executive function, behaviour problems and general health.
main outcome measuresThe main long-term outcome measure was a composite of abnormal development at the age of 2.5-5.5 years.
resultsOf the 426 women eligible for follow-up, 196 (46%) parents returned the questionnaires for 115 children in the nifedipine group and 110 children in the atosiban group. Abnormal development occurred in 32 children (30%) in the nifedipine group and in 38 children (38%) in the atosiban group (OR 0.74, 95% CI 0.41-1.34). The separate outcomes for neurodevelopment, executive function, behaviour, and general health showed no significant differences between the groups. Sensitivity analysis for all children of the APOSTEL III trial, including a comparison of deceased children, resulted in a higher rate of healthy survival in the nifedipine group (64 versus 54%), but there was no significant difference in the overall mortality rate (5.4 versus 2.7%). There were no significant subgroup effects.
conclusionOutcomes on broad child neurodevelopment, executive function, behaviour and general health were comparable in both groups. Neither nifedipine nor atosiban can be considered as the preferred treatment for women with threatened preterm birth. TWEETABLE ABSTRACT: Nifedipine- and atosiban-exposed children had comparable long-term outcomes, including neurodevelopment, executive function and behaviour.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.